Glecaprevir + Pibrentasvir

Kathryn Dzintars, Pharm.D., BCPS

INDICATIONS

FDA

  • Treatment of adult patients with chronic HCV infection (genotypes 1, 2, 3, 4, 5, or 6) without cirrhosis or compensated cirrhosis (Child-Pugh A).
  • Treatment of adult patients with HCV Genotype 1 infection previously treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: July 10, 2018